Although several clinical trials have demonstrated the survival benefit of anti-PD-1/PD-L1 inhibitors over docetaxel in pretreated NSCLC patients, this has not been proven in EGFR-mutant populations [18,21,24]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.